AlbuRx 5% 250 ml
Biological
CSL Behring
Total Payments
$26,370
Transactions
25
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $26,370 | 25 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $26,370 | 25 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)(CMV) | CSL Behring | $26,370 | 0 |
Top Doctors Receiving Payments for AlbuRx 5% 250 ml
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $26,370 | 25 |
Ad
Manufacturing Companies
- CSL Behring $26,370
Product Information
- Type Biological
- Total Payments $26,370
- Total Doctors 0
- Transactions 25
About AlbuRx 5% 250 ml
AlbuRx 5% 250 ml is a biological associated with $26,370 in payments to 0 healthcare providers, recorded across 25 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $26,370 was paid across 25 transactions to 0 doctors.
The most common payment nature for AlbuRx 5% 250 ml is "Unspecified" ($26,370, 100.0% of total).
AlbuRx 5% 250 ml is associated with 1 research study, including "A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)(CMV)" ($26,370).